1-3 of 3
Yoko Tabe, M.D., Ph.D.
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Inhibition of PI3K or Integrin-Linked Kinase (ILK) Target Primary AML Cells within the Bone Marrow Microenvironment in the In Vitro Co-Culture System.

Teresa McQueen, Yoko Tabe, M.D., Ph.D., Marina Konopleva, M.D., Ph.D., Michael Andreeff, M.D., Ph.D.
Journal: Blood
Blood (2006) 108 (11): 1903.
https://doi.org/10.1182/blood.V108.11.1903.1903
Published: 2006
Journal Articles

Mesenchymal Stem Cells Promote Survival of Leukemic Cells Via Integrin-Linked Kinase (ILK)-Dependent Akt and STAT3 Activation: Implications for Leukemia Therapy.

Yoko Tabe, M.D., Ph.D., Linhua Jin, Gordon B. Mills, M.D., Ph.D., Yuko Tsutsumi-Ishii, Michael Andreeff, M.D., Ph.D., Marina Konopleva, M.D., Ph.D.
Journal: Blood
Blood (2004) 104 (11): 3377.
https://doi.org/10.1182/blood.V104.11.3377.3377
Published: 2004
Journal Articles

Histone Deacetylase Inhibitor Depsipeptide (FK228) Induces Apoptosis through Histone Acetylation and Upregulation of Annexin A1 in AML1-ETO Expressing Kasumi-1 Cells.

Yoko Tabe, M.D., Ph.D., Rooha Contractor, Susanne Radke, Ph.D., Michael Andreeff, M.D., Ph.D., Marina Konopleva, M.D., Ph.D.
Journal: Blood
Blood (2004) 104 (11): 4343.
https://doi.org/10.1182/blood.V104.11.4343.4343
Published: 2004